6P95 image
Deposition Date 2019-06-09
Release Date 2019-09-11
Last Version Date 2024-10-30
Entry Detail
PDB ID:
6P95
Title:
Structure of Lassa virus glycoprotein in complex with Fab 25.6A
Biological Source:
Source Organism:
Lassa virus (Taxon ID: 11622)
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
3.50 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 61 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Pre-glycoprotein polyprotein GP complex
Gene (Uniprot):GPC
Mutations:R207C, L258R, L259RG
Chain IDs:A, B, C
Chain Length:180
Number of Molecules:3
Biological Source:Lassa virus
Polymer Type:polypeptide(L)
Molecule:FAB Antibody heavy chain
Chain IDs:D, F, H
Chain Length:231
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:FAB Antibody light chain
Chain IDs:E, G, I (auth: L)
Chain Length:217
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Pre-glycoprotein polyprotein GP complex
Gene (Uniprot):GPC
Mutations:G360P, M332T, E329C
Chain IDs:J (auth: a), K (auth: b), L (auth: c)
Chain Length:180
Number of Molecules:3
Biological Source:Lassa virus (strain Mouse/Sierra Leone/Josiah/1976)
Ligand Molecules
Primary Citation
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Cell 178 1004 1015.e14 (2019)
PMID: 31398326 DOI: 10.1016/j.cell.2019.07.020

Abstact

Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antibody responses is unclear. Here, we compared three crystal structures of LASV GPC complexed with GPC-B antibodies of varying neutralization potency. Each GPC-B antibody recognized an overlapping epitope involved in binding of two adjacent GPC monomers and preserved the prefusion trimeric conformation. Differences among GPC-antibody interactions highlighted specific residues that enhance neutralization. Using structure-guided amino acid substitutions, we increased the neutralization potency and breadth of these antibodies to include all major LASV lineages. The ability to define antibody residues that allow potent and broad neutralizing activity, together with findings from analyses of inferred germline precursors, is critical to develop potent therapeutics and for vaccine design and assessment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures